Literature DB >> 21570487

Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.

Sharon Kilbreath1, Kathryn M Refshauge, Jane Beith, Leigh Ward, Kate Sawkins, Ross Paterson, Philip Clifton-Bligh, Philip N Sambrook, Judy M Simpson, Liza Nery.   

Abstract

BACKGROUND: Aromatase inhibitors (AIs) have improved the prognosis for breast cancer survivors and are now standard of care for postmenopausal women with hormone receptor positive early stage breast cancer. One side-effect, however, is a decrease in bone mineral density (BMD) and increased fracture risk. Since hormone replacement therapy (HRT) is contraindicated in these women, one prevention option is exercise combined with vitamin D and calcium. The effect of this intervention on drug-induced osteoporosis is unknown.
METHODS: A single-blind randomized controlled trial will be undertaken to test the hypothesis that exercise combined with vitamin D and calcium can prevent the decrease in BMD associated with the use of AIs. Sixty postmenopausal women prescribed an AI for the treatment of breast cancer will be randomized into either an exercise or control group. Participants randomized to the exercise group will undertake a 12-month gym-based exercise program, 3 times per week involving resistance and impact training. Participants in the control group will be advised on the benefits of exercise for preventing osteoporosis, but not prescribed exercise. Both groups will receive vitamin D and calcium supplements. The primary outcome will be total hip bone mineral density measured via dual energy X-ray absorptiometry (DXA). Study outcomes will be compared between groups at baseline, 6months and 12months.
SUMMARY: This study will investigate the effect of exercise in combination with vitamin D and calcium on prevention of drug-induced osteoporosis in postmenopausal women prescribed AIs for the treatment of breast cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570487     DOI: 10.1016/j.cct.2011.04.012

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  4 in total

1.  Inhibition of caspase-3-mediated GSDME-derived pyroptosis aids in noncancerous tissue protection of squamous cell carcinoma patients during cisplatin-based chemotherapy.

Authors:  Zixian Huang; Qianyu Zhang; Yan Wang; Rui Chen; Yongqiang Wang; Zhuoshan Huang; Guangming Zhou; Haigang Li; Xi Rui; Tingting Jin; Shihao Li; Yin Zhang; Zhiquan Huang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  Osteoporosis and cancer.

Authors:  Matthew T Drake
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

3.  Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience.

Authors:  Evelyne Bischof; Fabienne D Schwab; Elena Laura Georgescu Margarint; Céline Montavon; Iris Zünti; Anna Schollbach; Andreas Schötzau; Anna Hirschmann; Julia Landin; Christian Meier; Kurzeder Christian; Marcus Vetter
Journal:  Bone Rep       Date:  2021-12-11

Review 4.  Physical activity for women with breast cancer after adjuvant therapy.

Authors:  Ian M Lahart; George S Metsios; Alan M Nevill; Amtul R Carmichael
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.